Trends in Fluoroquinolone (ciprofloxacin) Resistance in Enterobacteriaceae from Bacteremias, England and Wales, 1990-1999

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2002 May 9

PMID 11996681

Citations 31

Authors

David M Livermore

Dorothy James

Mark Reacher

Catriona Graham

Thomas Nichols

Peter Stephens

Alan P Johnson

Robert C George

Affiliations

Soon will be listed here.

Abstract

The Public Health Laboratory Service receives antibiotic susceptibility data for bacteria from bloodstream infections from most hospitals in England and Wales. These data were used to ascertain resistance trends to ciprofloxacin from 1990 through 1999 for the most prevalent gram-negative agents: Escherichia coli, Klebsiella spp., Enterobacter spp., and Proteus mirabilis. Significant increases in resistance were observed for all four species groups. For E. coli, ciprofloxacin resistance rose from 0.8% in 1990 to 3.7% in 1999 and became widely scattered among reporting hospitals. The prevalence of resistance in Klebsiella spp. rose from 3.5% in 1990, to 9.5% in 1996 and 7.1% in 1999, while that in Enterobacter spp. rose from 2.1% in 1990 to 10.5% in 1996 and 10.9% in 1999. For both Klebsiella and Enterobacter spp., most resistance was localized in a few centers. Resistance was infrequent and scattered in P. mirabilis, but reached a prevalence of 3.3% in 1999.

Citing Articles

County-level spatiotemporal distribution of fluoroquinolone-resistant Enterobacteriaceae in outpatient settings of the Veterans' Health Administration, 2000-2017.

Smith M, Carrel M, Goto M Infect Control Hosp Epidemiol. 2022; 44(9):1497-1499.

PMID: 36458687 PMC: 10507512. DOI: 10.1017/ice.2022.291.

Initial empirical antibiotics of non-carbapenems for ESBL-producing E. coli and K. pneumoniae bacteremia in children: a retrospective medical record review.

Park S, So H, Kim M, Lee J BMC Infect Dis. 2022; 22(1):866.

PMID: 36404302 PMC: 9677890. DOI: 10.1186/s12879-022-07881-7.

Changes of antibiotic prescribing pattern and its resistance to E. Coli in South Korea: a 12-year retrospective observational study.

Lee G, Ryu S, Park J, Lee E, Lee K, Tae J Sci Rep. 2021; 11(1):5658.

PMID: 33707496 PMC: 7970963. DOI: 10.1038/s41598-021-84450-z.

Estimating Factors Related to Fluoroquinolone Resistance Based on One Health Perspective: Static and Dynamic Panel Data Analyses From Europe.

Zhang D, Cui Y, Zhang X Front Pharmacol. 2019; 10:1145.

PMID: 31636561 PMC: 6787557. DOI: 10.3389/fphar.2019.01145.

Temporal association between antibiotic use and resistance in at a tertiary care hospital.

Ryu S, Klein E, Chun B Antimicrob Resist Infect Control. 2018; 7:83.

PMID: 30026941 PMC: 6048898. DOI: 10.1186/s13756-018-0373-6.

References

Kern W, Andriof E, Oethinger M, Kern P, Hacker J, Marre R . Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994; 38(4):681-7. PMC: 284525. DOI: 10.1128/AAC.38.4.681. View

Everett M, Jin Y, Ricci V, Piddock L . Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob Agents Chemother. 1996; 40(10):2380-6. PMC: 163538. DOI: 10.1128/AAC.40.10.2380. View

Yoo J, Huh D, Choi J, Shin W, Kang M, Kim C . Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. Clin Infect Dis. 1998; 25(6):1385-91. DOI: 10.1086/516132. View

Nema S, Premchandani P, Asolkar M, Chitnis D . Emerging bacterial drug resistance in hospital practice. Indian J Med Sci. 1997; 51(8):275-80. View

Martinez-Martinez L, Pascual A, Jacoby G . Quinolone resistance from a transferable plasmid. Lancet. 1998; 351(9105):797-9. DOI: 10.1016/S0140-6736(97)07322-4. View

Threlfall E, Cheasty T, Graham A, Rowe B . Antibiotic resistance in Escherichia coli isolated from blood and cerebrospinal fluid: a 6-year study of isolates from patients in England and Wales. Int J Antimicrob Agents. 1997; 9(3):201-5. DOI: 10.1016/s0924-8579(97)00055-1. View

Dennesen P, Bonten M, Weinstein R . Multiresistant bacteria as a hospital epidemic problem. Ann Med. 1998; 30(2):176-85. DOI: 10.3109/07853899808999401. View

Oethinger M, Jellen-Ritter A, Conrad S, Marre R, Kern W . Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection. 1998; 26(6):379-84. DOI: 10.1007/BF02770840. View

Zinner S . Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999; 29(3):490-4. DOI: 10.1086/598620. View

10.

Garau J, Xercavins M, Rodriguez-Carballeira M, COLL I, Vidal D, Llovet T . Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999; 43(11):2736-41. PMC: 89552. DOI: 10.1128/AAC.43.11.2736. View

11.

Renau T, Leger R, Flamme E, Sangalang J, She M, Yen R . Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem. 1999; 42(24):4928-31. DOI: 10.1021/jm9904598. View

12.

Reacher M, Shah A, Livermore D, Wale M, Graham C, Johnson A . Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ. 2000; 320(7229):213-6. PMC: 27266. DOI: 10.1136/bmj.320.7229.213. View

13.

Livermore D, Threlfall E, Reacher M, Johnson A, James D, Cheasty T . Are routine sensitivity test data suitable for the surveillance of resistance? Resistance rates amongst Escherichia coli from blood and CSF from 1991-1997, as assessed by routine and centralized testing. J Antimicrob Chemother. 2000; 45(2):205-11. DOI: 10.1093/jac/45.2.205. View

14.

Bauernfeind A, Petermuller C . In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol. 1983; 2(2):111-5. DOI: 10.1007/BF02001575. View

15.

Smith J . The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother. 1986; 18 Suppl D:21-9. DOI: 10.1093/jac/18.supplement_d.21. View

16.

. A guide to sensitivity testing. Report of the Working Party on Antibiotic Sensitivity Testing of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother. 1991; 27 Suppl D:1-50. View

17.

Maschmeyer G . Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts. Drugs. 1993; 45 Suppl 3:73-80. DOI: 10.2165/00003495-199300453-00014. View